Daptomycin: Difference between revisions
No edit summary |
No edit summary |
||
| Line 26: | Line 26: | ||
'''| [[Daptomycin clinical studies|Clinical Studies]]''' | '''| [[Daptomycin clinical studies|Clinical Studies]]''' | ||
'''| [[Daptomycin dosage and administration|Dosage and Administration]]''' | '''| [[Daptomycin dosage and administration|Dosage and Administration]]''' | ||
'''| [[Daptomycin how supplied|How Supplied]]''' | '''| [[Daptomycin how supplied|How Supplied]]''' | ||
'''| [[Daptomycin labels and packages|Labels and Packages]]''' | '''| [[Daptomycin labels and packages|Labels and Packages]]''' | ||
Revision as of 03:55, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Overview
Daptomycin is a novel lipopeptide antibiotic used in the treatment of certain infections caused by Gram-positive organisms. It is a naturally-occurring compound found in the soil saprotroph Streptomyces roseosporus. Its distinct mechanism of action means that it may be useful in treating infections caused by multi-resistant bacteria. It is marketed in the United States under the trade name Cubicin (Cubist Pharmaceuticals).
Category
Cyclic lipopeptide
US Brand Names
CUBICIN®.
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages